Beta Bionics earnings release, July 29, 2026

Beta Bionics, Inc. (BBNX) · Form 8-K, Item 2.02 · Filed · SEC filing

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.

Second Quarter 2026 Financial Highlights & Key Metrics

Net sales of $32.0 million, up 38% compared to $23.2 million in the second quarter of 2025.

Durable Medical Equipment (DME) channel net sales of $20.4 million, up 9% compared to $18.6 million in the second quarter of 2025.

Pharmacy Benefit Plan (PBP) channel net sales of $11.6 million, up 153% compared to $4.6 million in the second quarter of 2025.

Gross margin of 59.0%, up 524 basis points compared to 53.8% in the second quarter of 2025.

New patient starts increased by at least 10% but less than 20% sequentially versus the first quarter of 2026.

69% of new patient starts came from multiple daily injections (MDI).

High 30s percentage of new patient starts reimbursed through the PBP channel.

Loss from operations of $25.6 million, or negative 80% of sales, compared to $19.9 million or negative 86% of sales in the second quarter of 2025.

Net loss of $23.4 million, or negative 73% of sales, compared to $16.9 million or negative 73% of sales in the second quarter of 2025.

Adjusted EBITDA

(

1) of negative $17.7 million, or negative 55% of sales, compared to negative $14.5 million or negative 63% of sales in the second quarter of 2025.

$225.2 million in cash, cash equivalents, short and long-term investments as of June 30, 2026.

(¹)

See “Non-GAAP Financial Measures” below for additional information. A reconciliation of the non-GAAP financial measure to its most directly comparable GAAP financial measure can be found in Table D.

Recent Strategic Highlights

In July, initiated enrollment for a pivotal trial studying the iLet in adults with type 2 diabetes in the U.S.

Beta Bionics expects to expand iLet’s indications for use to adults with type 2 diabetes in the U.S. around mid-year 2027, subject to regulatory clearance by the FDA.

Announced updated expectations to fully commercialize Mint, Beta Bionics’ patch pump in development, by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA).

The company expects Mint manufacturing capacity to meet anticipated demand at full launch.

Published a near real-time real-world data dashboard publicly available on the company’s website, setting a new standard for data transparency in the Automated Insulin Delivery category.

In its most recent Phase 2a feasibility trial in New Zealand initiated in the first quarter of 2026 for the bihormonal system in development, the company identified opportunities to improve the glucagon asset’s excipient profile and the bihormonal dosing algorithm, with improvements expected to take less than one year prior to initiating additional feasibility trials.

2026 Full Year Guidance

Estimated total revenue of approximately $131 million to $136 million (no change versus previous guidance).

Estimated 37% to 39% of new patient starts reimbursed through the PBP channel (no change versus previous guidance).

Estimated gross margin of 58.5% to 59.5% (previously 57.5% to 59.5%).

Webcast & Conference Call Details

Beta Bionics will host a conference call and concurrent webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s second quarter 2026 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI3bd9f03fbd0f42bcb9f566c242240033

Non-GAAP Financial Measures

Beta Bionics, Inc. (the “Company”) prepares and presents the Company’s financial statements in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The Company believes adjusted EBITDA as a non-GAAP measure is useful in evaluating the Company’s operating performance and uses adjusted EBITDA to evaluate ongoing operations and for internal planning and forecasting purposes. The Company believes that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the Company’s performance by excluding certain items that may not be indicative of the Company’s business, results of operations, or outlook. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in the Company’s industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. A reconciliation is provided below for adjusted EBITDA to the most directly comparable financial measure stated in accordance with GAAP in Table D below.... (truncated)iation efforts in response to the FDA Form 483 and Warning Letter, including contractor support and various updates to the quality system.

Some of the limitations of adjusted EBITDA include: (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization expense are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. The Company’s adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as the Company calculates the measure, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future the Company will incur expenses similar to the adjustments in this presentation. The Company’s presentation of adjusted EBITDA should not be construed as an inference that the Company’s future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating the Company’s performance, you should consider adjusted EBITDA alongside other financial performance measures, including the Company’s net loss and other GAAP results.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate the Company’s business. This non-GAAP measure has limitations as an analytical tool and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. Therefore, this non-GAAP financial measure should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Financial statements

Income Statement

Beta Bionics, Inc. (In thousands, except number of shares and per share data)

Three Months EndedBeta Bionics, Inc. – Statements of Operations and Comprehensive Loss (unaudited) – Table A – Three Months Ended – June 30, – 2026Three Months EndedBeta Bionics, Inc. – Statements of Operations and Comprehensive Loss (unaudited) – Table A – Three Months Ended – June 30, – 2025Three Months EndedBeta Bionics, Inc. – Statements of Operations and Comprehensive Loss (unaudited) – Table A – Six Months Ended – June 30, – 2026Six Months EndedBeta Bionics, Inc. – Statements of Operations and Comprehensive Loss (unaudited) – Table A – Six Months Ended – June 30, – 2026Six Months EndedBeta Bionics, Inc. – Statements of Operations and Comprehensive Loss (unaudited) – Table A – Six Months Ended – June 30, – 2025Six Months Ended
Net sales32,01323,23859,63940,877
Cost of sales13,11110,73524,30019,403
Gross profit18,90212,50335,33921,474
Gross margin59.0%53.8%59.3%52.5%
Operating expenses:Research and development10,2408,87320,59616,463
Operating expenses:Sales and marketing24,64015,62345,37529,025
Operating expenses:General and administrative9,6007,87919,21714,500
Operating expenses:Total operating expenses44,48032,37585,18859,988
Operating expenses:Loss from operations-25,578-19,872-49,849-38,514
Other income (expense):Interest income2,1773,0054,5535,441
Other income (expense):Other expense-2-2-2-2
Other income (expense):Change in fair value of warrant liabilities-12,450
Other income (expense):Total other income (expense), net2,1753,0034,551-7,011
Other income (expense):Net loss-23,403-16,869-45,298-45,525
Other comprehensive income (loss):Unrealized gain (loss) on short-term and long-term investments-294-91-79384
Other comprehensive income (loss):Comprehensive loss-23,697-16,960-46,091-45,441
Other comprehensive income (loss):Net loss per share attributable to common stockholders, basic and diluted-0.53-0.39-1.02-1.23
Other comprehensive income (loss):Weighted-average common shares outstanding, basic and diluted44,545,29343,390,65244,554,14137,087,726
Other comprehensive income (loss):Beta Bionics, Inc.Beta Bionics, Inc.Beta Bionics, Inc.
Other comprehensive income (loss):Balance Sheets (unaudited)Balance Sheets (unaudited)Balance Sheets (unaudited)
Other comprehensive income (loss):Table BTable BTable B
Other comprehensive income (loss):(In thousands, except number of shares)(In thousands, except number of shares)June 30,December 31,
Other comprehensive income (loss):(In thousands, except number of shares)(In thousands, except number of shares)2,0262,025
Current assets:Cash and cash equivalents44,31831,576
Current assets:Restricted cash, current100100
Current assets:Short-term investments136,171187,549
Current assets:Accounts receivable, net18,05317,118
Current assets:Inventories23,91821,722
Current assets:Prepaid expenses and other current assets8,4749,840
Current assets:Total current assets231,034267,905
Current assets:Property and equipment, net10,7488,600
Current assets:Operating lease right-of-use asset5,8166,627
Current assets:Long-term investments44,64845,431
Current assets:Other long-term assets141180
Current assets:Total assets292,387328,743
Current liabilities:Accounts payable5,3514,998
Current liabilities:Accrued expenses and other current liabilities17,19422,431
Current liabilities:Operating lease liabilities1,5911,938
Current liabilities:Deferred revenue1,8811,557
Current liabilities:Total current liabilities26,01730,924
Current liabilities:Operating lease liabilities, net of current portion4,9215,365
Current liabilities:Deferred revenue, net of current portion3,4543,297
Current liabilities:Other long-term liabilities1,6291,547
Current liabilities:Total liabilities36,02141,133
Stockholders’ equity:Common stock, $0.0001 par value, 700,000,000 shares authorized; 44,981,606 and 44,360,873 issued and outstanding at June 30, 2026 and December 31, 2025, respectively54
Stockholders’ equity:Additional paid-in capital671,986657,140
Stockholders’ equity:Accumulated other comprehensive income (loss)-390403
Stockholders’ equity:Accumulated deficit-415,235-369,937
Stockholders’ equity:Total stockholders’ equity256,366287,610
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding its clinical and regulatory development plans for the iLet and other product candidates; the markets and market opportunities for the iLet, Mint, the bihormonal system and other product candidates, if approved; the timing, likelihood or success of its business strategy, including commercialization as well as plans and objectives of management for future operations; its anticipated growth and other measures of future operating results and financial performance, including 2026 full year guidance regarding estimates of revenue, new patient starts reimbursed through the PBP channel and gross margin; the design, results, and timing of its research and development efforts and planned trials for the iLet in adults with type 2 diabetes; the design, results and timing of its research and development efforts and feasibility trials for the bihormonal system in development, including the expected timelines with respect to improvements to the glucagon asset’s excipient profile and the bihormonal dosing algorithm; and the timing or certainty of the FDA’s approval of Mint, the timing or certainty of the commercialization of Mint and related updates and the Company’s manufacturing capacity at launch. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, including, without limitation, risks inherent in developing product candidates, future results from the Company’s ongoing and future studies and clinical trials, the Company’s ability to obtain adequate financing to fund its product development and other expenses, risks that real-world data or future results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:

Blake Beber

Head of Investor Relations ir@betabionics.com

Media and Public Relations:

Felicia Sanborn

Vice President of Marketing media@betabionics.com

Source: Beta Bionics, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Beta Bionics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.